RemeGen (688331.SH/09995.HK) announced that the 48-week open-label extension (OLE) data from China Phase III clinical study of telitacicept (RC18, brand name: 泰爱®, a BLyS/APRIL dual-target fusion ...

Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase 3 clinical trial in gMG is currently ...

Under the agreement, CSL will fully fund VarmX’s phase 3 trial of its lead candidate, VMX-C001, and retains an exclusive ...

VarmX announced its partnership with CSL, supporting the development of its lead asset VMX-C001, along with entering into an ...

LONDON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- The world’s first therapeutic drug to be equipped with NovalGen’s pioneering AutoRegulation (AR) technology has been approved for evaluation in the clinic by ...

Proteins perform their many different functions via physical interactions with other molecules, in particular, small ...

A researcher at the Hackensack Meridian Center for Discovery and Innovation (CDI) and physician-scientist colleagues from ...

Ubiquitin controls the lifespan and distribution of proteins in the cell, but it can also determine their shape, function, or ...

Regeneron Pharmaceuticals said on Wednesday its experimental treatment for a rare genetic disorder affecting soft tissue ...

A drug licensed from Pfizer will be submitted to the FDA next year after study results showed it reduced dermatomyositis ...

Treatment for blood cancers has significantly improved over the past 3-plus decades, with mortality rates for non-Hodgkin lymphoma and multiple myeloma declining by more than 40% and 30%, respectively ...

Academic, industry, and FDA collaboration is key to personalized treatment manufacturing, says Aldevron’s Max Sellman at BPI this week.